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ABSTRACT 
A large number of behavioural methods have been developed to evaluate the analgesic 
effect of drugs in animals, but many authors have been neglecting the importance of the 
assessment of drug induced neurotoxicity or drug induced motor impairment, sedation or 
stimulation, prior to the nociception tests. In the present work, two in vivo models for evaluation 
of drugs with potential analgesic activity were developed and fully implemented, using NMRi 
mice: one model was constituted by the formalin paw test associated with the rotarod test and the 
open-field test (FRO) and the other model was constituted by the writhing test, also associated 
with the rotarod test and the open-field test (WRO). 
The results obtained in the present study demonstrate that eslicarbazepine acetate 
(1 - 300 mg/kg) orally administered to NMRi mice 60 minutes before the tests produced 
dose-dependent antinociceptive activity in the two models tested (FRO and WRO). This effect 
was significant against chemically (formalin and acetic acid) induced nociception. The doses of 
the eslicarbazepine acetate, carbamazepine and oxcarbazepine that produced analgesia in the 
formalin paw and writhing tests were smaller in magnitude than those required to produce effects 
in both the rotarod and open-field tests. The ED50 value obtained for eslicarbazepine acetate in 
the formalin paw test was 41.1 (38.9 - 44.0) mg/kg and in the writhing test was 108.1 (97.4 - 
118.9) mg/kg. Moreover the results obtained for protective index (PI) of eslicarbazepine acetate, 
when compared with the protective indices for carbamazepine and oxcarbazepine show that 
eslicarbazepine acetate is just about 3-fold more protective against formalin induced-pain than 
carbamazepine and oxcarbazepine. In the writhing test, eslicarbazepine acetate has shown a PI 
between carbamazepine and oxcarbazepine. 
In conclusion, one can state that both models FRO and WRO are sensitive tools of great 
importance for the evaluation of the analgesic activity of both old and new drugs and the rotarod 
and the open-field tests together play an important role in the developed models. 
  
RESUMO 
Um grande número de métodos comportamentais para avaliação do efeito analgésico de 
fármacos em animais têm vindo a ser desenvolvidos, mas muitos autores têm vindo a 
negligenciar a importância da avaliação da neurotoxicidade induzida por fármacos ou da 
deficiência motora, sedação ou estimulação induzidas por fármacos, antes dos testes de 
nocicepção. No presente trabalho foram desenvolvidos e totalmente implementados dois modelos 
in vivo para avaliação de fármacos com potencial actividade analgésica, usando ratinhos NMRi: 
um modelo foi constituído pelo teste da formalina na pata, associado ao teste do “rotarod” e ao 
teste de campo aberto (FRO) e outro modelo foi constituído pelo teste das contorções 
abdominais, também associado ao teste do “rotarod” e ao teste de campo aberto (WRO). 
Os resultados obtidos no presente estudo demonstram que o acetato de eslicarbazepina 
(1 - 300 mg/kg) administrada oralmente a ratinhos NMRi 60 minutos antes dos testes produziu 
actividade antinociceptiva dependente da dose nos dois modelos testados (FRO e WRO). Este 
efeito foi significativo após nocicepção induzida por agentes químicos (formalina e ácido 
acético). As doses de acetato de eslicarbazepina, carbamazepina e oxcarbazepina que produziram 
analgesia nos testes da formalina na pata e das contorções abdominais foram mais reduzidas do 
que as necessárias para produzir efeito em ambos os testes de “rotarod” e de campo aberto. O 
valor de ED50 obtido para o acetato de eslicarbazepina no teste de formalina na pata foi 41,1 
(38,9 - 44,0) mg/kg e no teste das contorções abdominais foi 108,1 (97,4 - 118,9) mg/kg. Os 
valores obtidos para o índice de protecção (PI) do acetato de eslicarbazepina, quando comparados 
com os índices de protecção para a carbamazepina e oxcarbazepina, mostram que o acetato de 
eslicarbazepina é cerca de 3 vezes mais protector contra a dor induzida pela injecção de formalina 
do que a carbamazepina ou a oxcarbazepina. No teste das contorções abdominais, o acetato de 
eslicarbazepina apresentou um PI entre o da carbamazepina e o da oxcarbazepina. 
Em conclusão, pode constatar-se que ambos os modelos FRO e WRO são ferramentas 
sensíveis de grande importância para a avaliação da actividade analgésica de fármacos clássicos e 
contemporâneos e que os testes de “rotarod” e de campo aberto em conjunto, desempenham um 
papel importante nos modelos desenvolvidos. 
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1 Pain 
Pain has been part of the human experience for more than 50,000 years. Pain has been a 
very real and immediate concern in all ages, but the attitudes and responses of people to pain 
have been shaped by magical, theological, demonological, philosophical, and practical influences 
in varying degrees with shifting emphasis (Kucharski and Todd, 2008). 
Pain is the most frequent reason patients seek medical advice. Pain is the body's 
mechanism of self-preservation. There is no consensual definition for pain, but it was described 
by the International Association for the Study of Pain, in November 2007, as “An unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or described 
in terms of such damage”. Pain tells you when your finger is touching a hot surface or when a fall 
has resulted in an injury that requires your attention. In this way, pain acts as a warning sign to 
alert you when damage to your body is occurring or may occur. Also, pain promotes the healing 
process as we take great care to protect an injured body part from further damage to minimize the 
experience of more pain. In fact, the inability to experience pain is a dangerous condition, 
because injury can occur and go unnoticed. Those individuals who are born with conditions in 
which they lack nociceptors (receptors for noxious stimuli), tend to live short lives due to their 
inability to recognize the pain stimuli as a signal for potential or ongoing tissue damage.  
Pain can be classified in different ways. From the point of view of its aetiology, pain can 
be nociceptive induced or it can be neuropathic. Nociceptive pain refers to pain arising from 
direct exogenous (mechanical, chemical, thermical, and electrical) or endogenous (inflammation, 
and tissue ischemia) stimulation of nociceptors, such as occurs with trauma or inflammation. 
Neuropathic pain refers to pain arising from damage to the nervous system. Pain can also be 
spontaneous, associated with psychological factors and so called psychogenic (Dubner and 
Hargreaves, 1989). Some types of mental or emotional problems can cause, increase, or prolong 
pain. 
From the point of view of its duration, pain can be classified in acute pain and chronic 
pain. Acute pain occurs for brief periods of time and it is always an alarm signal that something 
may be wrong. Chronic pain (also referred to as “persistent pain”) is continuous and recurrent and 
is one of the symptoms of chronic diseases. The boundaries between acute and chronic pain are 
16 
 
 
not defined. Acute pain can range from momentary pain (may last a few seconds or as long as the 
stimulus is applied) to several hours or days after an injury (also referred to as “clinical pain”) 
while chronic pain is defined as pain that lasts more than three months, whether it is due to a 
continuous inflammatory process or a neuropathy (a disease or abnormality of the nervous 
system) (Purves et al., 2008) . 
Scientific evidence gathered over the years made it clear that many different mechanisms 
modulate the transmission of nociceptive information at every level of the nervous system. The 
first evidence of the existence of a pain modulation system was the observation that electrical 
stimulation of discrete areas of the brain inhibited responses to painful stimuli (Fields and Adams, 
1974). At about the same time, the discovery of opiate receptors and of endorphins provided 
insight into the manner in which narcotic analgesics relieve pain. It is now generally accepted that 
pain modulation is achieved through a series of complex interactions between inputs from the 
periphery, interneurons in the spinal cord and descending control systems from the brain (Fields, 
1984). 
In the last twenty years, extraordinary progress has been made on understanding the 
physiology of pain (Purves et al., 2008). The discovery of a complex nervous system network for 
the modulation of pain, and the isolation and description of endorphins had a great contribute to 
our understanding of pain transmission (Steeds, 2009). Nevertheless there are still many areas of 
the physiology of pain that remain unknown. The physiology of pain involves nociceptors, 
combined with an intricate system of afferent and efferent neuronal connections. Nociceptors are 
relatively unspecialized nerve cell endings that initiate the sensation of pain (noci- is derived 
from the Latin for “hurt”) (Purves et al., 2008). All nociceptors are free nerve endings that are 
sensitive to painful mechanical stimuli, extreme heat or cold, and chemical stimuli. Most pain 
originates when nociceptors are stimulated and nerve impulses are transmitted to the brain 
through the pain pathways. It is important to note that almost all body tissues are equipped with 
nociceptors, an important fact considering pain has primary warning functions. Nociceptors can 
be classified in two types: unimodal receptors and polymodal receptors (Nathan, 1976; Bonica, 
1990). Unimodal receptors, also known as mecanothermal nociceptors, are mainly present in the 
skin and respond to strong pressure applied to the skin and strong stimuli as pinprick or sudden 
heat (greater than 45°C). This type of receptor is mainly associated with small myelinated 
primary afferent neurons designated Aδ type that transmits impulses rapidly. Stimulation of this 
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type of receptor results in pain that occurs early after injury and is usually sharp, well-localized, 
and pricking (Nathan, 1976; Bonica, 1990). Polymodal receptors are the free nerve endings of 
unmyelinated primary afferent neurons of the C type which are widely distributed throughout 
most tissues and respond to tissue damage (Nathan, 1976; Bonica, 1990). The best known theory 
describing how painful stimuli may be altered at the spinal level is the Gate Control Theory 
(Melzack and Wall, 1965). The Gate Control Theory is illustrated in Figure 1. This theory 
postulates that painful stimuli have to pass through a gate in order to be communicated to the 
central nervous system, lacking one-to-one correspondence between the severity of the stimulus 
and the severity on pain experience. According to this theory, the peripheral nervous system 
communicates with the central nervous system through a complex interplay: upon injury, pain 
messages originated in the nociceptors associated with the damaged tissue flow along the 
peripheral nerves to the spinal cord where they encounter “nerve gates” that open or close 
depending upon a number of factors, after which the modulated pain messages reach the brain. 
So, the modulation of the pain messages occurs at the spinal cord level. When the gates are open, 
pain messages reach the brain more or less easily and pain can be intense. When the gates are 
closed, pain messages are prevented from reaching the brain without even being experienced. The 
spinal cord receives inputs from 2 types of nerve fibers: Aδ fibers and the C-fibers (Steeds, 
2009). A typical example of the Gate Control Theory is that after bumping one’s knee, rubbing 
the area seems to provide some relief because this action activates other sensory nerve fibers that 
are even “faster” than Aδ fibers which send information about pressure and touch that reach the 
spinal cord and brain, overwriting some of the pain messages carried by the Aδ fibers and the C-
fibers (Steeds, 2009). 
One of the most critical aspects in pain research is its assessment; pain is a highly 
complex phenomenon that by its nature presents assessment difficulties. Pain is a subjective 
experience which is difficult to express and quantify, and is not directly measurable. Further 
difficulties occur since individual patients react to similar painful stimuli in many different ways. 
In addition many factors are known to influence pain response. They include ethnicity, sex, age, 
culture, personality, the type, duration and intensity of pain, and other psychological variables 
such as fear, anxiety and stress. However, the measurement of pain is essential for the study of its 
mechanisms and for the evaluation of pain control methods. 
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Figure 1: Illustration of the Gate Control Theory proposed 
Melzack and Wall in the 1960's. Available from 
http://www.garysturt.free-online.co.uk/pain.htm 
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2 Animal Models of Pain 
Throughout history, scientists have performed experiments on animals to understand 
animal and human biological structure and function. Practical, economical and scientific reasons 
make preliminary studies in animals the best solution for studies of a human biological 
phenomenon. A laboratory animal model describes a biological observable fact that the species 
has in common with the target species, being “analogy” the key word for understanding the 
concept of animal models (Rose and Woodbury, 2001). What is generally understood by the term 
animal model is modelling humans. The focus of research is not the used animal but the analogy 
of physiological behaviour of this animal to our own species. The practice of studying biological 
phenomena and diseases in laboratory animal models is well established in biomedical sciences 
(Rose and Woodbury, 2001). The valid “extrapolatability” of results generated in an animal 
model depends on the selection of a suitable animal model. Induced animal models involve 
healthy animals in which the condition to be investigated is experimentally induced.  
Animal models of pain have been invaluable tools for understanding pain mechanisms. To 
study pain transmission, identify new pain targets and characterize the potential analgesic profile 
of novel compounds, an array of experimental animal pain models has been developed (mainly in 
rodents) attempting to replicate the many human pain conditions, including inflammatory, 
neuropathic, visceral and cancer pain states (Walker et al., 1999; Joshi and Honore, 2006). The 
experience of pain is necessary for survival, so it is reasonable to assume that the mechanisms of 
pain perception are highly conserved across species (Liebeskind, 1991). This assumption has led 
to a vast array of important findings concerning pain via experiments conducted in rodents 
(Liebeskind, 1991). Animal models of pain are mostly models of nociceptive pain (pain arising 
from an identifiable lesion causing tissue damage, accompanied by stimulation of nociceptors in 
somatic or visceral structures) (Steeds, 2009). In animals, as well as in humans, in order to study 
pain of any kind, the appropriate stimuli must be applied in order to provoke the desired pain 
sensation. Different nociceptive pain tests use different stimuli with different characteristics: (i) 
stimulus may be thermal, mechanical or chemical; (ii) may or may not produce tissue damage; 
(iii) and may produce a short or a long lasting pain response (Franklin and Abbott, 1989).  
Animal models of nociceptive pain have been developed as assays of pain behaviour and 
fall mainly into two categories: (i) those that employ an acute nociceptive stimulus and that are 
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concerned with short-term nociceptive responses; (ii) and those that are concerned with the long-
term responses (Walker et al., 1999; Rose and Woodbury, 2001).  
There are two main types of methods for assessing pain, based on the duration of the 
applied stimulus: (i) the response to the stimulation is fixed and stimulation intensity increases 
until a defined standard response occurs; (ii) the stimulus is standardized, and the strength and 
duration of response is measured (e.g. the formalin paw test and the writhing test) (Meyer and 
Svendsen, 2003). The formalin paw test and the writhing test constitute methods for the 
measurement of pain by behavioural responses to stimulation of nociceptors by injection of 
irritant substances and are amongst the most frequently used contemporary models of pain (Rose 
and Woodbury, 2001). 
 
2.1 Formalin Paw Test 
The formalin paw test represents a model of moderate continuous pain, suitable for the 
evaluation of mild analgesics (Hunskaar et al., 1985). The chemical stimulation involving the 
administration of formalin is a progressive stimulation, with a duration in the order of minutes 
and with an inescapable character once it has been applied (Le Bars et al., 2001). In 1939, Lewis 
and Kellgren injected small volumes of hypertonic saline to produce experimental pain in humans 
(Tjolsen et al., 1992). This kind of work preceded the use of formalin as a noxious agent for 
animals (Tjolsen et al., 1992). Dubuisson and Dennis (1977) introduced the formalin test, 
administering 50 µl of 5 % formalin under the dorsal surface of a forepaw of rats and cats.  
Following subcutaneous injection of formalin into the hindpaw of an animal, it displays 
spontaneous pain behaviour that is increased hindpaw licking/biting. The formalin paw 
induced-pain response is difficult to assess in the forepaws of rodents, because normal grooming 
behaviour is typically based on animals licking the forepaws. The response to licking the 
hindpaws is assumed to be nociceptive (Tjolsen et al., 1992). The formalin-induced pain has been 
reported to be quantified in many different ways. Dubuisson and Dennis originally created 
behavioural categories that were used to assess formalin-induced pain by the weighted score 
method of behavioural rating (Coderre et al., 1993). Others used cumulative score methods to 
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assess pain-evoked responses, using a single parameter, such as scoring the total amount of time 
spent licking, biting or shaking the injected paw (Hunskaar and Hole, 1987). 
Characteristically the formalin paw test produces a biphasic response, with the two phases 
being distinguished pharmacologically. An early acute phase (first phase) occurring immediately 
after the injection of the diluted formalin solution lasts for about 3 - 5 minutes, which is thought 
to be caused by direct chemical stimulation of nociceptors (Abbott et al., 1995). A 10 - 15 
minutes gap between the two phases occurs until the second phase begins (Tjolsen et al., 1992). 
The first phase is considered by some authors to be the early acute phase together with the gap 
between the two phases lasting for about 15 minutes (Abbott et al., 1995). A later tonic phase 
(second phase) starting 15 minutes after the formalin injection and lasting for no more than 40 
minutes, is believed to occur due to a peripheral inflammatory process mediated by 
prostaglandins (Tjolsen et al., 1992).  
Formalin is the most common substance used as noxious stimuli for intradermal injections 
in several animal species. (Wheeler-Aceto and Cowan, 1991). Formalin is an aqueous solution of 
37 % (w/v) formaldehyde. A range of 0.02 to 5 % formalin solution concentrations have been 
reported in mice, with the most often injected volumes ranging from 20 to 25 µl (Tjolsen et al., 
1992). It has been demonstrated that the subcutaneous injection of different concentrations of 
formalin may induce the first phase or both phases; formalin concentrations of 0.05 to 0.2 % 
induce high licking/biting activity only in the first phase and formalin concentrations of 1 % or 
higher induce high licking/biting activity on both the first and the second phases (Rosland et al., 
1990).  
It has been reported that there are sex differences in the pain–related responses. Female 
mice show lower pain–related responses compared to males in the formalin paw test (Capone and 
Aloisi, 2004). Experimental results suggest that estrogen reduces the efficacy of endogenous pain 
modulation mechanisms, triggering an increase in spinal nociceptive neuronal activity (Spooner 
et al., 2007). 
Many publications refer to the mouse paw formalin test being done using mice habituated and 
not habituated to the testing environment and handling (Capone and Aloisi, 2004). Exposure to 
handling-induced stress or to a new environment strongly influences the formalin-induced 
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behaviour in mice (Tjolsen et al., 1992). Animals should be well adapted to the test observation 
chamber because the occurrence of the typical exploratory activity of animals in a new 
environment could distract them from the formalin-induced pain response. They should also be 
well habituated to handling and restraining because any abnormal discomfort may provoke stress 
in the animals which can mask the formalin-induced pain results.  
 
2.2 Writhing Test 
The writhing test consists of intraperitoneal injection of agents that irritate serous 
membranes, inducing a very typical behaviour in the mouse and rat which is characterized by 
abdominal contractions, movements of the hindpaws and twisting of dorsoabdominal muscles 
(Hendershot and Forsaith, 1959). Some authors consider these behaviours as resulting from 
visceral pain and others reject this hypothesis and consider the pain as arising from peritoneal 
pain (Le Bars et al., 2001). Several compounds are used, the most common being the acetic acid. 
Several modifications to this method have been made over the years, mainly concerning the 
chemical agent which causes the stimulus, its concentration and the volume of the injected 
solution. 
Acetic acid is an algogenic substance that directly activates peripheral nociceptors on the 
sensory nerve fibers by inducing capillary permeability and releasing endogenous substances that 
excite pain nerve endings (pro-inflammatory substances) producing inflammation of visceral 
(subdiaphragmatic) and subcutaneous (muscle wall) tissues (Cervero, 1995). This produces the 
characteristic ‘writhing response’: lengthwise stretches of the torso with a concomitant concave 
arching of the back and extensions of the hind limbs (Collier et al., 1968; Bentley et al., 1981). 
Mice and rats present a very stereotyped behaviour when administered intraperitoneally with 
agents that irritate the serous membranes (Rose and Woodbury, 2001).  
The acetic acid-induced writhing is a pain model widely used for detecting peripheral 
analgesia (Du et al., 2007). The original test was described in 1957 by Siegmund et al. and used 
phenylbenzoquinone as irritating agent but since then many modifications have been made to the 
method mainly concerning the chemical agent that, in turn, determines the duration of the effect: 
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acetylcholine, dilute hydrochloric acid, bradykinin, adrenaline, potassium chloride, tryptamine, 
ocytocin and acetic acid have all been used (Le Bars et al., 2001). Modifications to the 
concentration, temperature, and volume of the injected solution, the experimental conditions, and 
ways of monitoring behavioural changes have also been made in order to simplify the test and 
increase its sensitivity (Le Bars et al., 2001). This method has the advantage of allowing evidence 
to be obtained for effects produced by weak analgesics (Le Bars et al., 2001). Because all 
analgesics inhibit abdominal cramps, this method is useful for sorting through molecules whose 
pharmacodynamic properties are unknown (Le Bars et al., 2001). 
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3 Other Behavioural Models 
 
3.1 Rotarod Test 
The loss of motor coordination is one of the most promptly observed effects of drug 
intoxication. The rotarod test is widely used in biomedical research as one of the most commonly 
used tests of motor incoordination in rodents. Dunham and Miya (1957) were the first to describe 
a fixed speed rotating rod, called by these authors “rolling roller apparatus” for detecting 
neurological deficits in rats and mice. It is frequently used in early stages of drug development to 
screen-out drugs that might later cause impairment in human motor behaviour. Ataxia (loss of 
motor coordination) is a frequent endpoint for studies of drug intoxication. One of the most 
commonly used behavioural models of ataxia is the rotarod test (Rustay et al., 2003). The rotarod 
test assesses the effect of drugs on an animal’s balance and coordination or fatigue resistance on 
mice and rats, by measuring the amount of time that an animal is able to remain on a 
longitudinally rotating rod. Animals have to keep their balance on a rotating textured rod. When 
an animal drops onto the individual sensing platforms below, test results are recorded. 
Performance is measured by the time that an animal stays on the rod as a function of drum speed.  
Many different rotarod systems are available from a number of companies, but almost all 
apparatus will automatically record the time at which the animal falls, and allow several animals 
to be tested at the same time (Carter et al., 2001). Many significant modifications have been made 
to the basic design of the first described rotarod test, like accelerating the rod continuously until 
the mouse or rat can no longer balance and fall, changing rod diameters from 3 - 8 cm, using 
fixed-speed rates of 3 - 31 rpm and acceleration rates of 3.5 - 60 rpm/min (Rustay et al., 2003). 
There are two basic versions of the rotarod test that are widely used: the fixed-speed and the 
accelerating-speed rotarod (Rustay et al., 2003; Monville et al., 2006). There is still little 
information on their equivalence or the relative power, reliability and sensitivity of the two 
protocols. The fixed-speed rotarod system allows changing parameters as rod diameter, 
maximum time limit for performance and rate of rotation, and requires extensive training of the 
animals. The accelerating-speed rotarod system eliminated the existence of a maximal time limit 
for performance, providing a model that starts at a slow speed allowing all animals to stay on and 
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accelerating at a constant rate until it becomes difficult enough so that all animals would 
eventually fall off (Rustay et al., 2003). This model allows for the measurement of drug-induced 
increased in performance, which is difficult to observe using a low rotation rate in the fixed-speed 
model. 
Some strains of rodents are not suitable for usage in the rotarod test due to their 
propensity to jump from the rod instead of running on top. Also some strains have a propensity to 
hold onto the rod and instead of actively completing the task, they passively rotate around. 
Rustay et al. (2003) engineered a way to circumvent this confounding factor by using a rod of 6.3 
cm of diameter, which was large enough to prevent most mice from being able to hold to the rod, 
avoiding passive rotation. These authors also recommend that, independently of the usage of a 
fixed-speed or accelerating-speed rotarod system, mice should be trained to a stable level of 
performance before drug administration so that changes seen after drug administration are the 
result of drug action and not due to effects on learning on the apparatus (Rustay et al., 2003). 
 
3.2 Open-field Test 
Open-field test is a common measure of general locomotion activity and exploratory 
behaviour in rodents (Walsh and Cummins, 1976). It was first developed by Hall in 1934 
(Choleris et al., 2001) and it is commonly used to assess the sedative, toxic, or stimulant effects 
of compounds (Gould et al., 2009). The open-field test was defined by Choleris et al. (2001) as 
“an enclosed open area where an animal is placed and some form of behaviour, usually activity, 
is measured”. The open-field test was widely used in psychology and it has gradually spreaded 
out to neurosciences and psychopharmacology (Tvrdeic and Kocevski, 2008). The original 
studies were in rats, but this test has also been extensively used in mice (Gould et al., 2009).  
This test allows the measurement of both qualitative and quantitative activity. But, 
although sometimes the open-field test is considered a “standard test”, many factors can vary 
among studies like size of the open field arena, shape, level of illumination, single exposure 
versus repeated exposure to the open-field arena, duration of testing, time of day of testing, food 
and water deprivation, sex of the animals, predator odour in the arena (Choleris et al., 2001). 
Most of the automated open-field test systems allow the measurement of the locomotor activity 
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by determining the amount of distance travelled as well as the various horizontal, vertical and 
stereotyped behaviours like time spent along the walls compared to time spent in the centre, 
distance moved over different time periods, and rearing. Typically, in psychopharmacological 
studies, animals are naive to the open-field arena and the effects of the pharmacological agents on 
the duration and frequency of some behaviour like locomotion and rearing are assessed (Choleris 
et al., 2001). 
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4 Antiepileptics as Adjuvant Analgesics 
Pain can be treated in several different ways. Analgesics are drugs that relieve pain 
without blocking the conduction of nerve impulses or markedly altering the function of the 
sensory apparatus (Álamo and López-Muñoz, 2007). Analgesics are taken both to control acute 
and chronic pain. Analgesics are classified is three categories: (i) opioid analgesics, also called 
narcotics; (ii) non-opioid analgesics, also called non steroidal anti-inflammatory drugs – 
NSAIDs; and (iii) adjuvant analgesics, which are drugs with a primary indication other than pain 
but that have analgesic properties (Lussier et al., 2004; Becker and Phero, 2005). 
Throughout the clinical usage of antiepileptic drugs, it has been observed that these drugs 
can be used in many diseases other than epilepsy. Antiepileptic drugs are already used in the 
treatment of bipolar disorder (Dilsaver et al., 1996), impulse control disorder (Berlin, 2008), 
eating disorders (Kaplan et al., 1983) and specially to manage pain (McQuay et al., 1995). 
Antiepileptic drugs have been used in the management of pain since the 1960s (McQuay et al., 
1995). The presence of common clinical and physiopathological characteristics between epilepsy 
and several pain types made possible the usage of different antiepileptic drugs as they would 
appear in the market (Álamo and López-Muñoz, 2007). In 1912, phenobarbital, the first 
antiepileptic drug was marketed, but the appearance of more antiepileptic drugs has occurred at a 
very slow step (Álamo and López-Muñoz, 2007). One group of antiepileptic drugs containing 
carbamazepine and that is called nowadays classic antiepileptic drugs, was commercialized just 
before 1970 (Álamo and López-Muñoz, 2007). In 1990 more antiepileptics such as 
oxcarbazepine were marketed, being more effective, presenting less adverse effects and showing 
better pharmacokinetic and pharmacodynamic characteristics than the previously marketed 
antiepileptic drugs (Álamo and López-Muñoz, 2007). In 2009, about twenty years later, 
eslicarbazepine acetate was developed as a new antiepileptic drug which is structurally related to 
carbamazepine and oxcarbazepine, but with improved tolerability profiles and efficacy (Dulsat et 
al., 2009). 
 
4.1 Carbamazepine 
Carbamazepine (Figure 2) was first introduced in 1963 in Switzerland and in the United 
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Kingdom for clinical treatment of epileptic seizures and has become the most frequently 
prescribed first-line drug for the treatment of partial and generalized tonic-clonic epileptic 
seizures all over the world (Araujo et al., 2004).  
Although it is very effective in the majority of cases, soon it started showing a number of 
unwanted side effects. In clinical trials, about 10 to 25% of patients administered with 
carbamazepine showed adverse effects, with a higher incidence in the elderly (Sillanpaa et al., 
2009). Carbamazepine active epoxide metabolite is the responsible for a number of adverse 
effects associated with carbamazepine therapy (Grant and Faulds, 1992). The main metabolic 
pathway is epoxidation which is catalysed primarily by the cytochrome P450 and results in the 
formation of a pharmacologically active carbamazepine epoxide metabolite, contributing to both 
therapeutic and adverse effects (Sillanpaa et al., 2009). Carbamazepine clinical application is 
complicated by the potent induction of hepatic oxidative metabolism, the potential for adverse 
reactions and its slow and variable absorption (Hainzl et al., 2002).  
 
N
NH2O  
 
Figure 2: Chemical structure of carbamazepine. 
 
Carbamazepine has been used for the treatment of neuropathic pain in humans. Recently, 
several studies have reported that carbamazepine has antinociceptive activity, for it has shown to 
be effective in different animal models of acute pain induced by inflammatory, thermal and 
mechanical nociceptive stimuli (Aoki et al., 2006).  
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4.2 Oxcarbazepine 
Oxcarbazepine (Figure 3) was introduced commercially in Denmark in 1990, has been 
available throughout the European Union since 1999 and was launched in 2000 in the USA for 
the management of seizures (Faught and Limidi, 2009). Oxcarbazepine is an antiepileptic drug 
derived from carbamazepine.  
Oxcarbazepine is the 10 - keto analogue of carbamazepine with a differing metabolic 
profile that manages to circumvent the carbamazepine adverse effects, retaining similar 
therapeutic utility (Grant and Faulds, 1992). After administration, oxcarbazepine is rapidly 
reduced to an active metabolite that is present in human plasma at much higher concentrations 
than the parent drug and that is the principal active agent (Faught and Limidi, 2009). 
Oxcarbazepine and its metabolite are neutral lipophylic agents that might be expected to easily 
pass through the blood-brain barrier and are widely distributed in the body without any 
significant affinity to a particular site (Álamo and López-Muñoz, 2007). The elimination of the 
double bond between C-10 and C-11 prevents oxidative attack by an epoxidase, which is what 
occurs with carbamazepine. It has a better side-effect profile and many fewer metabolic drug-
drug interactions than carbamazepine, because it is metabolized by a non cytochrome P450 
pathway (Grant and Faulds, 1992).  
 
 
 
Figure 3: Chemical structure of oxcarbazepine. 
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Oxcarbazepine exerted analgesic effects in animal models of neuropathic, inflammatory, 
somatic, and visceral pain (Tomic et al., 2010). The mechanisms of analgesia of oxcarbazepine 
are not completely understood but it was demonstrated that it suppresses peripheral sensory nerve 
firing, probably by blockade of sodium currents, and also affects some receptors involved in pain 
modulation to produce antinociception (Tomic et al., 2010). 
 
4.3 Eslicarbazepine Acetate 
Eslicarbazepine acetate (Figure 4) is a drug clinically developed for the treatment of 
epilepsy, with EMEA recently granting marketing authorization to BIAL (Dulsat et al., 2009). It 
is currently under clinical development for the treatment of neuropathic pain (Almeida et al., 
2008; Almeida et al., 2009). 
 
 
 
Figure 4: Chemical structure of eslicarbazepine acetate. 
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Eslicarbazepine acetate is a novel voltage-gated sodium channel blocker, designed to 
share with carbamazepine and oxcarbazepine the dibenzazepine nucleus bearing the 
5-carboxamide substitute, but it is structurally different at the 10,11-position (Benes et al., 1999; 
Hainzl et al., 2001; Almeida and Soares-da-Silva, 2007). This molecular variation results in 
differences in metabolism which, among other things, prevents the formation of toxic epoxide 
metabolites (Almeida and Soares-da-Silva, 2003). Eslicarbazepine acetate mainly undergoes 
metabolic hydrolysis followed by glucoronidation with minimal CYP-mediated metabolism 
(Almeida et al., 2009). Oral administration of eslicarbazepine acetate to humans results in very 
low plasma concentrations of parent compound which is extensively biotransformed to 
S-licarbazepine by first-pass hydrolytic metabolism, being clearly the major circulating drug 
(Almeida et al., 2008).  
There have been no concerning findings for human use of eslicarbazepine acetate, based 
on conventional preclinical studies of safety, pharmacology, toxicology, genotoxicity, 
reprotoxicity and carcinogenity, which makes believe that its use will undoubtedly increase in the 
future (Almeida et al., 2009). 
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5 Objectives 
 
5.1 General Objective 
Development and implementation of animal models for evaluation of drugs with potential 
analgesic activity, in NMRi mice. 
 
5.2 Specific Objectives 
• Development and implementation of the formalin paw test in mice; 
• Development and implementation of the writhing test in mice; 
• Development and implementation of the rotarod test in mice;  
• Development and implementation of the open-field test in mice; 
• Examination of the dose-dependent effect of eslicarbazepine acetate on antinociception 
using the formalin paw and the writhing tests, on motor function using the rotarod test and 
on spontaneous exploratory behaviour and general activity using the open-field test; 
• Determination of the protective index of eslicarbazepine acetate. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
MATERIAL AND METHODS 
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1 Reagents 
All reagents and solutions used in all experimental procedures were of at least standard 
laboratory grade. The water used was obtained from an ultra-pure water producing system. 
The reagents used and their respective suppliers are presented next: 
- Acetic Acid (Sigma-Aldrich®); 
- Carbamazepine (Sigma-Aldrich®); 
- Carboxymethyl cellulose (Sigma-Aldrich®); 
- Eslicarbazepine Acetate (BIAL-Portela & Cª, S.A.); 
- Ethanol (Sigma-Aldrich®); 
- Formalin solution 10 % (Sigma-Aldrich®); 
- Morphine (Sigma-Aldrich®); 
- Oxcarbazepine (ChemPacific); 
- Sodium Chloride (Sigma-Aldrich®). 
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2 Drugs, Solutions and Treatment Groups 
Administered vehicle was carboxymethyl cellulose (CMC) 0.5 % in ultra-pure water. 
The test drug eslicarbazepine acetate, the comparison drugs carbamazepine and 
oxcarbazepine and the reference drug morphine were dispersed in CMC 0.5 %. 
Formalin (5 %) was obtained by dilution of the formalin solution 10 % in sodium chloride 
0.9 % in ultra-pure water. 
Acetic acid (0.8 %) was obtained by dilution of acetic acid reagent in sodium chloride 
0.9 % in ultra-pure water. 
Animals administered with the vehicle substance were considered to be the control group. 
Animals administered with the different concentrations of the test drug eslicarbazepine acetate (1 
- 450 mg/kg), the comparison drugs carbamazepine (100 and 300 mg/kg) and oxcarbazepine (100 
and 300 mg/kg), and the reference drug morphine (64 mg/kg) were considered to be the treated 
groups. 
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3 Laboratory Equipment 
The laboratory equipment used is presented next:  
- 26 gauge needle attached to a micro syringe by PE10 tubing; 
- 29 gauge needle attached to a micro syringe by PE10 tubing; 
- Automatic Pipettes Gilson PIPETMAN®; 
- Balance Kern® ABJ; 
- Balance Mettler Toledo® XP26; 
- Chronometer; 
- Magnetic Stirrer IKA®; 
- Manual counter; 
- MilliQ water system (Millipore ®); 
- Mirror; 
- Plexiglass observation chambers (20 x 26 x 26 cm); 
- Potentiometer WTW® pH 3000 with coupled electrode SenTix® 21; 
- Rotarod apparatus with a rotating cylinder with a 6.3 cm diameter rod (Ugo Basile 
Biological Research Apparatus); 
- San Diego Instruments Photobeam Activity System – Open Field composed by:  
o Clear acrylic enclosure (40 cm wide x 40 cm deep x 38 cm high);  
o Photobeam mounding frame (with 16 photobeams in each direction, spaced by 
2.5 cm);  
o Rear frame;  
o Control unit;  
- Ultrasonic bath; 
- Vortex mixer SA8 Stuart®. 
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4 Softwares 
The softwares used for data collection and data analysis are the ones described next: 
- GraphPad Prism® 5.02 (GraphPad Software, Inc.); 
- Microsoft® Office Excel 2007; 
- Photobeam Activity System Control software for Windows 2000/XP (version 2.0). 
 
5 Animals 
 
5.1 Species Used 
Male NMRi mice, 30 - 40 g body weight range were used. They were supplied by Harlan 
Interfauna Ibérica, S. L., Spain. 
 
5.2 Animal Housing 
Animals were delivered to the laboratory (Laboratory of Pharmacological Research of the 
Department of Research and Development at BIAL - Portela & Cª S. A.) 2 weeks before the 
experiment, during which time they were acclimatized to the laboratory conditions. They were 
housed in groups of 5 in macrolon cages (25 x 19 x 13 cm) on wood litter (Litalabo - SPPS, 
95100 Argenteuil, France) with free access to food (food certified by Harlan Teklab Global 
Diet®) and water until the day before being tested. The animal house was maintained under 
artificial lighting (12 hours) between 8 am and 8 pm, at controlled ambient temperature of 
22 ± 2 ºC, and relative humidity of 60 ± 10 %. 
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5.3 Ethical Aspects 
The EC directive states that an animal should not be kept alive after an experiment if pain 
is experienced. At the end of the experiment, animals were sacrificed by the mechanical-physical 
method of dislocation of the cervical vertebrae, by stretching the animal and rotating the neck, 
away from the presence of other animals, which constitutes a painless method (Hellebrekers et 
al., 2001). These procedures were executed in accordance with the recommendations of the 
Federation of European Laboratory Animal Science Associations (FELASA), which is in 
accordance with the European Directive no. 86/609 and with the Portuguese legislation (Decreto-
Lei 129/92, Portarias 1005/92 and 1131/97). The number of animals used was the minimum 
possible in compliance with current regulations and scientific integrity. 
 
5.4 Justification for the Choice of Species, Route of Administration and Dose Levels 
The choice of the species for a chosen animal model depends on the homology and 
evolutionary similarity between morphological structures and physiological processes between 
animals and humans (Beynen and Hau, 2001). Although mice and rats have many concurrent 
biological characteristics, they do not necessarily serve equally well as models of human malady. 
Mouse was chosen as animal model because of economical advantages and also because mice 
have shown the most similar metabolism to humans after administration of eslicarbazepine 
acetate (Alves et al., 2008).  
The route of administration of compounds and vehicle were chosen based on the intent of 
oral administration of the compounds to humans. Mice animals were deprived of food for 18 
hours prior to the experiment to avoid any possible food-drug interaction. 
 The study included several doses for the assessment of pain. The chosen doses were 
based on the envisage determination of the effective doses for analgesic effect on the developed 
models. 
To avoid any possible effect of the circadian rhythm in the animal models of pain 
developed during this experimental work, half of the tested animal for each group were tested in 
the morning and half in the afternoon. 
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6 Rotarod Test 
The rotarod test allows the assessment of motor coordination and balance in rodents. Using 
rotating rods allows one to evaluate the duration that mice and rats can maintain balance at a 
defined rotating speed. Dunham and Miya (1957) described the first rotating rod for detecting 
neurological deficit in rats and mice. 
 
6.1 Habituation to Test Environment 
The newly acquired mice were housed for one week prior to being brought to the testing 
room for habituation. Adaptation was carried out in the testing room by transferring the animals, 
in their home cages, from the housing room to the testing room 2 hours before the training trials 
or before the test (Carter et al., 2001). For habituation to the rotating rod (Figure 5), two days and 
on the day before the experiment, each mouse was placed individually on the rotating rod and 
allowed to habituate to the forced motor activity for up to 60 seconds. Upon fall, each animal was 
returned to its home cage and allowed an inter-trial interval of 5 minutes. Mice were trained until 
they were able to remain on the rod for 2 consecutive trials (Carter et al., 2001). On the day of the 
experiment all animals were tested for their ability to stay on the rod for at least 60 seconds, to 
obtain the pre-drug time spent on the rod. Habituation to restraining and handling was performed 
between 8.00 am and 5.00 pm on the day before the rotarod test. 
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6.2 Experimental Procedure 
The rotarod apparatus had a 6.3 cm diameter rod, suitably machined to provide grip and a 
fall high of 17 cm (Rustay et al., 2003). In this apparatus, a motor sets the rotor in motion via the 
gear belt at a selected speed. When the mouse falls off its cylinder section, the plate below trips 
and the corresponding counter disconnects, thereby recording the animal’s endurance time in 
seconds. The machine was set at a revolving consistent speed of 15 rpm; always before training 
the animals or testing them, the rotarod apparatus was manually calibrated so that it was 
revolving at a consistent speed of 15 rpm (Stepanovic-Petrovic et al., 2008).  
 
 
 
Figure 5: Rotarod apparatus for testing motor coordination. 
 
 During the training sessions and at the end of testing each animal, the apparatus was 
thoroughly cleaned with 70 % (v/v) ethanol. The reason for this last described procedure is that 
animals defecate and urinate while on the rod and urine and faeces on the rod can impair the 
performance of the animals. 
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After adaptation of the animals to the testing room, the animals were separated in groups 
and each group was constituted by 10 animals under study, being each animal tested only once. 
Mice were placed on the rod while it was moving. The vehicle, test, comparison or reference 
drugs were administered orally 59 minutes before the test. All groups were administered by oral 
gavage at dosing volume of 8 ml/kg of body weight. Motor impairment was assessed for 60 
seconds. 
The time that the animal remained walking on the rod was scored in seconds, with the task 
ending when the animal fell off the rotarod or completed the 60 seconds trial. Many authors are 
concerned about how to score passive rotation when the animal grips on to the rotarod. That 
problem was circumvented here by using a 6.3 cm diameter rod, as proposed by Rustay et al. 
(2003). This author observed that using rods with 6.3 cm diameter or greater, the number of 
animals gripping on to the rotarod was neglectable.  
 
6.3 Data Presentation 
The results are expressed as mean ± S.E.M. (standard error of the mean) of the time spent 
on the rotarod in seconds. MS Excel was used to calculate mean and S.E.M.. 
The TD50 (the dose that induces motor impairment in 50 % of animals tested) was 
calculated from a corresponding quantal dose–response curve, with 95 % confidence limits. The 
Boltzmann sigmoidal equation was used to derive the TD50 value. GraphPad Prism was used to 
calculate the TD50 value. 
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7 Open-Field Test 
The open-field test was introduced in the 1930s by Calvin Hall (Leroy et al., 2009). The 
open-field test is a common measure of spontaneous exploratory behaviour and general activity 
in rodents that is often used to assess the sedative, toxic and stimulant effects of drugs. Recent 
open-field test systems allow registering general motor activity, locomotion, rearing and the 
speed of locomotion.  
 
7.1 Habituation to Test Environment 
The newly acquired mice were housed for one week prior to being brought to the testing 
room for habituation. Adaptation was carried out in the testing room by transferring the animals, 
in their home cages, from the housing room to the testing room 2 hours before the test and by 
transferring the animals from the rotarod to the open-field arena. Habituation to handling was 
performed between 8.00 am and 5.00 pm. The open-field test system is shown in Figure 6. 
 
 
Figure 6: Photobeam Activity System – Open Field. 
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7.2 Experimental Procedure 
The open-field arena consisted of an empty and transparent square arena, surrounded by 
walls that prevent the animal from escaping. A setup frame was mounted to fit a clear acrylic 
enclosure (40 cm wide x 40 cm deep x 38 cm high). The frame contains 2 rows of photobeams 
(16 photobeams mounted in each direction), spaced by 2.5 cm. Above the photo beam frame a 
rear frame was mounted to allow quantification of the number of rears that the animal performed. 
The photobeam frame was placed 30 mm above the top of the bench and the rear frame placed 80 
mm above the top of the bench. Interruptions of the photobeams were collected by a computer by 
means of Photobeam Activity System Control software. Two parameters were evaluated: 
ambulation and rearing. Ambulation allows the assessment of normal motor activity and rearing 
allows the assessment of exploratory behaviour. The software identifies these two parameters as: 
• Ambulation - all interruption of the photobeams in the lower rows; 
• Rearing - interruption of the photobeams in the upper rows (rear frame). 
After adaptation of the animals to the testing room, the animals were separated in groups of 
10 mice with each animal being tested only once. The vehicle, test, comparison or reference 
drugs, were administered orally 60 minutes before the test by oral gavage at dosing volume of 
8 ml/kg of body weight. The same grouped mice tested for the rotarod test were tested in the 
open-field test. So, immediately after the rotarod test, mice were placed in the centre of the arena 
and allowed to explore for 15 minutes. 
 
7.3 Data Presentation 
The results are expressed as mean ± S.E.M. of the ambulation frequency and of the 
rearing frequency. Frequencies were defined as the number of occurrences per 15 minutes test 
time. MS Excel was used to calculate mean and S.E.M..  
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8 Formalin Paw Test 
The formalin paw test was used to assess the antinociceptive effect of the administered 
drugs. The test described here is a modification of the one proposed by Hunskaar et al. (1985).  
 
8.1 Habituation to Test Environment 
Newly acquired mice were housed for one week prior to being brought to the testing room 
for habituation. Adaptation was carried out in the testing room on the day before the experiment 
by placing the animals singly in the observation chambers for 2 hours and on the day of the 
experiment by transferring the animals, in their home cages, from the housing room to the testing 
room 2 hours before the formalin paw test. The mouse observation chambers were clear 
plexiglass chambers with a mirror placed behind the chamber wall to allow an unobstructed view 
of the tested paw. Habituation to restraining and handling was performed between 8.00 am and 
5.00 pm on the day before the formalin paw test. The observation chamber is shown in Figure 7, 
as well as a counter and a chronometer. 
 
Figure 7: Observation chamber, chronometer and counter. 
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8.2 Experimental Procedure 
After adaptation of the animals to the testing room, testing chamber, handling and 
restraining, using a 26 gauge needle attached to a micro syringe by PE10 tubing, 25 µl of the 5 % 
formalin was injected subcutaneously into the left dorsal part of the hindpaw of the mouse 
(Figure 8). Each animal was manually gently restrained in such a way that allowed the referred 
injection to occur. After the injection of the nociceptive stimulus, the animals were allowed to 
move freely during the observation period. 
 
 
Figure 8: Subcutaneous injection of formalin solution in the 
dorsal part of the left hindpaw of the mouse. 
 
The vehicle, test, comparison or reference drugs, were administered orally 60 minutes 
before the test (i.e. 45 minutes before formalin) by oral gavage at a dosing volume of 8 ml/kg of 
body weight. Each group was composed of 10 animals under study. Each animal was tested only 
once and the tested paw was marked with a colour marker prior to the formalin injection, to allow 
46 
 
 
a clear observation of the formalin pain-evoked behaviour. 
The mice were observed from 15 to 30 minutes following formalin injection. During the 
first 15 minutes post formalin injection, pain behaviour reflects the early phase of the formalin 
paw test and readings were neglected. The late phase of the formalin paw test is observed via pain 
behaviour in the 15 to 30 minutes time period following formalin injection and the pain-evoked 
behaviour was scored for this phase. The amount of time that each animal spent licking or biting 
the injected paw (pain-evoked behaviour) was timed with a chronometer. No food or water was 
available during the test. Figure 9 shows a mouse executing the typical pain-evoked behaviour 
caused by subcutaneous injection of formalin in the dorsal part of the left hindpaw. 
 
 
Figure 9: Mouse licking formalin injected paw after 
subcutaneous injection of formalin solution in the dorsal part of 
the left hindpaw. 
47 
 
 
8.3 Data Presentation 
The results are expressed as mean ± S.E.M. of the amount of time that each animal spent 
licking or biting the injected paw after subcutaneous injection of formalin into the left dorsal part 
of the hindpaw of the mouse or as % protection conferred by orally administered drugs versus the 
vehicle administered group. The % protection was calculated as follows: 
 
100
FCmean 
FTmean -FCmean Protection % ×=     (1) 
 
“FCmean” represents the mean result for the amount of time that the control group mice 
spent licking/biting the injected paw following formalin injection. 
“FTmean” represents the mean result for the amount of time that the treated group mice 
spent licking/biting the injected paw following formalin injection. 
MS Excel was used to calculate mean, S.E.M. and % protection values.  
The values of ED50 (the dose that was antinociceptive in 50 % of animals tested) were 
estimated from the corresponding log dose-response curve, with 95 % confidence limits. 
GraphPad Prism was used to calculate the ED50 values. 
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9 Writhing Test 
The antinociceptive effect of the administered drugs was assessed using the acetic 
acid-induced writhing test. The test described here is a modification of the one proposed by 
Collier et al. (1968). 
 
9.1 Habituation to Test Environment 
As for the formalin test, newly acquired mice were housed for one week prior to being 
brought to the testing room for habituation. Adaptation was carried out in the testing room on the 
day before the experiment by placing the animals singly in the observation chambers (Figure 7) 
for 2 hours and on the day of the experiment by transferring the animals, in their home cages, 
from the housing room to the testing room 2 hours before the writhing test. A mirror was placed 
behind the observation chamber wall to allow an unobstructed view of the acetic acid 
pain-evoked behaviour revealed by the animal. Habituation to restraining and handling was 
performed between 8.00 am and 5.00 pm on the day before the writhing test. 
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9.2 Experimental Procedure 
After adaptation of the animals to the testing room, testing chamber, handling and 
restraining, using a 29 gauge needle attached to a micro syringe by PE10 tubing, mice were 
injected intraperitoneally with a 0.8 % (v/v) acetic acid solution (10 ml/kg of body weight) as an 
irritant stimulus and placed in the observation chamber for observation. Each animal was 
manually gently restrained in such a way that allowed the referred injection to occur. After the 
injection of the nociceptive stimulus, the animals were allowed to move freely during the 
observation period. Figure 10 shows the intraperitoneal injection of acetic acid solution to the 
mouse. 
 
 
Figure 10: Intraperitoneal injection of acetic acid solution. 
 
For the assessment of antinociception using the acetic acid-induced writhing test, the 
animals were separated in groups of 10 animals and each animal was tested only once. The 
vehicle, test, comparison or reference drugs were administered orally 60 minutes before the test 
and their ability to reduce the acetic acid pain-evoked behaviour was determined. All groups were 
administered by oral gavage at dosing volume of 8 ml/kg of body weight. 
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After the intraperitoneal injection of the acetic acid solution, the acetic acid pain-evoked 
behaviour was assessed. Five minutes post acetic acid injection, the number of accumulated 
writhes was recorded for 10 minutes, using a manual counter. A writhe consists of the contraction 
of the abdominal muscles accompanied by stretching of the hind limbs (Collier et al., 1968; 
Bentley et al., 1981). Figure 11 shows a characteristic writhe of a mouse injected 
intraperitoneally with acetic acid. 
 
 
Figure 11: Mouse performing a writhe in the writhing test. 
51 
 
 
9.3 Data Presentation 
The results are expressed as mean ± S.E.M. of the number of writhes induced by the 
intraperitoneal injection of acetic acid or as % protection conferred by orally administered drugs 
versus the vehicle administered group. The % protection was calculated as follows: 
 
100
WCmean 
 WTmean-WCmean Protection % ×=     (2) 
 
“WCmean” represents the mean result for the number of writhes performed by the control 
group mice following acetic acid injection. 
“WTmean” represents the mean result for the number of writhes performed by the treated 
group mice following acetic acid injection. 
MS Excel was used to calculate mean, S.E.M. and % protection values. 
The value of ED50 was estimated from the corresponding log dose-response curve, with 
95% confidence limits. GraphPad Prism was used to calculate the ED50 value. 
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10 Statistical Analysis 
Statistical analysis was done using software GraphPad Prism.  
Statistical analysis of the data was evaluated by means of one-way ANOVA, applied to 
pairs of data for unpaired samples. For comparisons made between the treated and control groups, 
one-way ANOVA was followed by Dunnett’s test. For comparisons made between all pairs of 
data, the post hoc Bonferroni test was applied. 
All differences between pairs of data were considered significant when the null hypothesis 
could be rejected at a risk α of less than 0.05 (p < 0.05). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III 
RESULTS 
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1 Rotarod Test and Open-Field Test 
 
1.1 The Effect of Eslicarbazepine Acetate, Carbamazepine and Oxcarbazepine in the 
Rotarod Test in Mice 
 Mice were examined for motor incoordination in the rotarod test. All mice were trained to 
a stable level of performance before drug administration so that changes seen after drug 
administration are the result of drug action and not due to effects on learning on the apparatus. 
In the rotarod test in mice, eslicarbazepine acetate (1 - 450 mg/kg) did not cause a 
reduction of the time spent on the rotarod, compared with the control group, except at the highest 
administered dose that caused a significant reduction. Carbamazepine (100 and 300 mg/kg) and 
oxcarbazepine (100 and 300 mg/kg) produced significant toxic effects on motor performance in 
mice compared with the control group but only at the highest tested dose (300 mg/kg). The effect 
on motor performance of mice orally administered with eslicarbazepine acetate (1 - 450 mg/kg.), 
carbamazepine (100 and 300 mg/kg.) and oxcarbazepine (100 and 300 mg/kg) are presented in 
Figure 12.  
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Figure 12: Effect of eslicarbazepine acetate, carbamazepine and oxcarbazepine orally 
administered doses on motor performance of mice expressed as time spent on rotarod (seconds). 
Each point represents the mean ± S.E.M. of time spent on the rotarod obtained for 10 animals. 
Significant differences between vehicle and all doses administered for each treated group are 
indicated by * (p < 0.05) and *** (p < 0.001) (Dunnett’s test subsequent to one-way ANOVA). 
 
The median toxicity dose (TD50) value for eslicarbazepine acetate-induced motor 
impairment is shown in Figure 13. The TD50 in mice for eslicarbazepine acetate was 
342.5 mg/kg, a value that is superior to that of carbamazepine (91.0 mg/kg) and of oxcarbazepine 
(239.4 mg/kg), accordingly with previously published data (Stepanovic-Petrovic et al., 2008). 
These values indicate that the motor incoordination caused by eslicarbazepine acetate is much 
lower than that caused by carbamazepine or oxcarbazepine. 
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Figure 13: The median toxicity dose (TD50) value for eslicarbazepine acetate-induced motor 
impairment in mice. Data was fitted using nonlinear regression with goodness of fit (R2) of 
0.980. The Boltzmann sigmoidal equation was used to derive the TD50 value of 
342.5 ± 6.4 mg/kg (TD50 value ± standard error) with 95% confidence intervals of 329.8 to 
355.3. The number of mice for each dose group was ten. 
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1.2 The Effect of Eslicarbazepine Acetate, Carbamazepine and Oxcarbazepine in the 
Open-Field Test in Mice 
In order to assess sedative, stimulant or general behaviour impairment effects on drug 
treated mice, animals were tested in an open-field arena, immediately after the rotarod test. The 
behavioural parameters - ambulation and rearing - were observed for 15 min. Ambulation and 
rearing reflect mostly exploratory activities. Typical behaviour in mice is high ambulation and 
high rearing when exposed to the open-field. 
Exposure to all dose levels of eslicarbazepine acetate, shown by the number of ambulation 
and number of rearing in the open-field arena during the observed period, caused no significant 
behavioural effects in mice except for the highest tested dose 450 mg/kg. The ambulation and 
rearing frequencies (number of occurrences per 15 minutes) for eslicarbazepine acetate in the 
open-field test are shown in Figures 14 and 15, respectively. 
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Figure 14: The ambulation frequency in the open-field test after oral administration of 
eslicarbazepine acetate (1 – 450 mg/kg). Each bar represents the mean ± S.E.M. of number of 
ambulations during 15 minutes observation time obtained for 10 animals. Significant differences 
between vehicle and all administered doses are indicated by *** (p < 0.001) (Dunnett’s test 
subsequent to one-way ANOVA). 
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Figure 15: The rearing frequency in the open-field test after oral administration of 
eslicarbazepine acetate (1 – 450 mg/kg). Each bar represents the mean ± S.E.M. of number of 
rearing during 15 minutes observation time obtained for 10 animals. Significant differences 
between vehicle and all administered doses are indicated by *** (p < 0.001) (Dunnett’s test 
subsequent to one-way ANOVA). 
 
As for eslicarbazepine acetate, the intact nature of motor functions and exploratory 
behaviour was also observed for the lower tested dose of carbamazepine (100 mg/kg) but on the 
other hand this was not observed for the highest tested dose of carbamazepine (300 mg/kg). Also 
there were no significant differences in any of the parameters evaluated in animals 60 minutes 
after treatment with oxcarbazepine 100 and 300 mg/kg. Results for ambulation and rearing 
frequencies for carbamazepine and oxcarbazepine tested doses are presented in Figure 16. 
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Figure 16: The open-field test for carbamazepine (100 and 300 mg/kg) and oxcarbazepine 
(100 and 300 mg/kg) orally administered. (A) Number of ambulations during 15 minutes 
observation time. (B) Number of rearing during 15 minutes observation time. Each bar 
represents the mean ± S.E.M. for 10 mice. Significant differences between vehicle and drug 
administered groups are indicated by *** (p < 0.01) (Dunnett’s test subsequent to one-way 
ANOVA). 
 
Orally administered eslicarbazepine acetate did not alter the motor behaviour in 
the open-field and rotarod tests at the doses of 1 mg/kg to 300 mg/kg neither did 
carbamazepine 100 mg/kg or oxcarbazepine 100 mg/kg.  
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2 Formalin Paw Test 
The formalin paw test is a classical model of nociception in mice. Two phases of behaviour 
follow injection of formalin into the hindpaw. The spontaneous pain behaviour in mice consists 
of intense licking or biting of the injected paw. In this study only the late phase of the formalin 
test was used to assess the analgesic activity of eslicarbazepine acetate, because it is described as 
being related to a peripheral inflammatory pain, while the early phase is due to a direct effect on 
nociceptors (Collier et al., 1968; Hunskaar and Hole, 1987). Pain behaviour was scored as the 
amount of time spent licking or biting the injected paw, in seconds. 
 
2.1 The Effect of Eslicarbazepine Acetate, Carbamazepine and Oxcarbazepine in the 
Formalin Paw Test in Mice 
The formalin paw test developed in this experimental work was validated using morphine 
orally administered at a high dose (64 mg/kg) to obtain a maximal effective response (Grognet et 
al., 1982). The anticonvulsants carbamazepine and oxcarbazepine were included as comparison 
substances to the effect of eslicarbazepine acetate in the late phase of formalin paw test in mouse 
(Shannon et al., 2005). The late phase was evaluated between 15 and 30 minutes after injection of 
formalin.  
Morphine completely abolished the formalin-induced licking or biting (p < 0.001). Both 
carbamazepine and oxcarbazepine significantly decreased licking or biting the injected paw, 
conferring protection of 93.3 % and 84.5 % respectively, compared with control vehicle. As 
morphine, eslicarbazepine acetate (300 mg/kg) conferred a 100 % protection against pain, as 
compared with control vehicle. Individual values (mean ± S.E.M.) for the formalin-induced 
licking or biting after oral administration of the anticonvulsants eslicarbazepine acetate, 
carbamazepine and oxcarbazepine and the opioid morphine are presented in Table 1. 
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Table 1: The effects of different doses of eslicarbazepine acetate and single doses of 
carbamazepine, oxcarbazepine and morphine in the late phase of the formalin paw test 
(evaluated between 15 and 30 minutes after injection of formalin) in mouse. 
 Treatment (mg/kg) 
p.o. 60 min before the test (i.e. 45 min before formalin) mean S.E.M. p  value
Vehicle 87.6 12.3 - 0.0
Eslicarbazepine acetate (1) 84.2 4.3 NS 3.9
Eslicarbazepine acetate (10) 66.5 8.4 NS 24.1
Eslicarbazepine acetate (30) 48.6 9.2 < 0.05 44.5
Eslicarbazepine acetate (100) 29.5 11.4 < 0.01 66.3
Eslicarbazepine acetate (200) 10.1 3.2 < 0.001 88.5
Eslicarbazepine acetate (300) 0.0 0.0 < 0.001 100.0
Carbamazepine (100) 5.3 5.2 < 0.001 93.9
Oxcarbazepine (100) 13.6 7.6 < 0.001 84.5
Morphine (64) 0.0 0.0 < 0.001 100.0
% Protection
(15 to 30 min after formalin)
Licking / bitting time (sec)
 
Each group represents the mean ± S.E.M. for the formalin-induced licking or biting (in seconds) 
for 10 animals. Significant differences between vehicle and eslicarbazepine acetate, 
carbamazepine, oxcarbazepine and morphine treated groups calculated by means of one-way 
ANOVA followed by Dunnett’s test. P values less than 0.05 were regarded as statistically 
significant.  
 
Oral administration of eslicarbazepine acetate (1, 10, 30, 100, 200 and 300 mg/kg) caused 
a dose-dependent reduction in the time that the animals spent licking or biting the injected paw, 
as compared with control. This dose-dependent reduction was significant at all tested doses 
except at the lower tested doses 1 and 10 mg/kg (Figure 17). 
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Figure 17: Effect of eslicarbazepine acetate orally administered in the late phase of the formalin 
paw test (15 – 30 min). Pain behaviour was scored as the amount of time spent licking or biting 
the injected paw in seconds. Each bar represents the mean ± S.E.M. for 10 animals. Statistical 
analysis of the data was evaluated by means of one-way ANOVA followed by Dunnett’s test 
between vehicle and eslicarbazepine acetate treated groups. Significances are indicated by 
* (p < 0.05), ** (p < 0.01) or *** (p < 0.001). 
 
Observing the plot in Figure 18, although there is no significant difference in the 
inhibition of pain when eslicarbazepine acetate is administered as compared with the other tested 
anticonvulsants or morphine, it is clear that eslicarbazepine acetate has a more prominent 
protection against pain as compared with carbamazepine and oxcarbazepine. The protection was 
at the morphine protection level, completely abolishing the licking or biting pain-evoked 
behaviour (Table 1). 
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Figure 18: Protective effect of oral administration of vehicle (V), eslicarbazepine acetate (ESL) 
300 mg/kg, carbamazepine (CBZ) 100 mg/kg, oxcarbazepine (OXC) 100 mg/kg and 
morphine (M) 64 mg/kg on the nociceptive reaction to subcutaneous injection of formalin in the 
hindpaw of mice. Each bar represents the mean ± S.E.M. for 10 animals. Statistical analysis of 
the data was evaluated by means of one-way ANOVA followed by Bonferroni’s multiple 
comparison test between all groups with significances indicated by # p < 0.001 for all groups 
compared to vehicle.  
 
The antinociceptive activity of eslicarbazepine acetate in the formalin paw test was 
evaluated by the ED50 value. It was calculated by orally administering 1 - 300 mg/kg of the 
referred anticonvulsant to mice. The ED50 value obtained for eslicarbazepine acetate 60 
minutes after treatment was 41.4 mg/kg (Figure 19). 
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Figure 19: ED50 value for eslicarbazepine acetate licking/biting response in the late phase of the 
formalin paw test. Eslicarbazepine acetate was orally administered 60 minutes before the 
formalin paw test. Data was fitted using nonlinear regression with a goodness of fit (R2) of 
0.988. The Gompertz equation was used to derive the ED50 value (41.4 ± 1.3 mg/kg). 
 
In the view of the data (Table 1) indicating that at 100 mg/kg carbamazepine is more 
protective against formalin pain-evoked behaviour than oxcarbazepine at the same 
administered dose and also because the literature lacks the information, the ED50 value for 
carbamazepine in the formalin paw test was determined. The ED50 value obtained for 
carbamazepine 60 minutes after oral administration was 40.3 mg/kg (Figure 20). 
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Figure 20: ED50 value for carbamazepine licking/biting response in the late phase of the 
formalin paw test. Carbamazepine was orally administered 60 minutes before the formalin paw 
test. Data was fitted using nonlinear regression with a goodness of fit (R2) of 1.000. The 
Gompertz equation was used to derive the ED50 value (40.3 ± 0.1 mg/kg). 
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3 Writhing Test 
The writhing test is also, as the formalin paw test, a classical model of nociception in mice, 
being used by many researchers to evaluate the potential analgesic properties of several different 
drugs. The behavioural scoring in mice consisted of writhing production shortly after the 
intraperitoneal injection of acetic acid. A writhe was defined as stretching of both hind limbs 
accompanied by a contraction of the abdominal muscles.  
 
3.1 The Effect of Eslicarbazepine Acetate, Carbamazepine and Oxcarbazepine in the 
Writhing Test in Mice 
In the experiments done in this experimental work to develop and implement the writhing 
test, morphine was used to validate the model and the anticonvulsants carbamazepine and 
oxcarbazepine were tested as comparison drugs to the analgesic effect of eslicarbazepine acetate. 
 The effects of eslicarbazepine acetate, carbamazepine, oxcarbazepine and morphine on 
acetic acid-induced writhing behaviour in mice are shown in Table 2. The per cent protection 
values produced by eslicarbazepine acetate (300 mg/kg), carbamazepine (100 mg/kg) and 
oxcarbazepine (100 mg/kg) were 91.3 %, 62.1 % and 68.3 % respectively. Morphine (64 mg/kg) 
completely abolished the number of writhes induced by acetic acid in mice, conferring a 
complete protection against pain. 
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Table 2: The effects of different doses of eslicarbazepine acetate and single doses of 
carbamazepine, oxcarbazepine and morphine in the writhing test (evaluated for 10 minutes, 
starting 5 minutes after injection of acetic acid) in mouse. 
 Treatment (mg/kg) 
p.o. 60 min before the test mean S.E.M. p  value
Vehicle 35.6 2.3 - 0.0
Eslicarbazepine acetate (1) 33.2 1.8 NS 6.7
Eslicarbazepine acetate (10) 31.3 2.3 NS 12.1
Eslicarbazepine acetate (30) 25.5 2.8 < 0.01 28.4
Eslicarbazepine acetate (100) 22.7 1.4 < 0.001 36.2
Eslicarbazepine acetate (200) 12.1 2.3 < 0.001 66.0
Eslicarbazepine acetate (300) 3.1 0.7 < 0.001 91.3
Carbamazepine (100) 13.5 1.4 < 0.001 62.1
Oxcarbazepine (100) 11.3 1.7 < 0.001 68.3
Morphine (64) 0.0 0.0 < 0.001 100.0
Number of writhes (s)
(5 min after acetic acid for 10 min)
% Protection
 
Each group represents the mean ± S.E.M. for the acetic acid- induced writhing (in seconds) 
for 10 animals. Significant differences between vehicle and eslicarbazepine acetate, 
carbamazepine, oxcarbazepine and morphine treated groups calculated by means of one-way 
ANOVA followed by Dunnett’s test. P values less than 0.05 were regarded as statistically 
significant.  
 
Eslicarbazepine acetate (30, 100, 200 and 300 mg/kg) when administered orally, 
dose-dependently and significantly reduced the number of writhes induced by acetic acid in mice. 
The lower doses 1 and 10 mg/kg did not interfere with the acetic acid pain-evoked effect as 
compared with vehicle (Figure 21).  
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Figure 21: Effect of eslicarbazepine acetate in the writhing test, expressed as number of writhes 
induced by p.o. injection of acetic acid in mice. Each point represents mean ± S.E.M. for 10 
animals. Significant differences between vehicle and drug administered groups are indicated by 
* (p < 0.05) and *** (p < 0.001) (Dunnett’s test subsequent to one-way ANOVA). 
 
After statistical analysis of the pain inhibitory effect of eslicarbazepine acetate, the other 
anticonvulsants tested and morphine, many differences were observed (Figure 22). Morphine as 
expected completely abolished the writhes provoked by acetic acid intraperitoneal injection 
conferring a 100 % inhibition of the pain-evoked behaviour. Eslicarbazepine acetate conferred a 
decrease in the number of writhes at the same level as morphine, with no statistical significant 
difference between the two referred results. When comparing the inhibitory effect of 
eslicarbazepine acetate with the pain-evoked inhibition conferred by carbamazepine and 
oxcarbazepine, eslicarbazepine acetate was more analgesic, with statistically significant 
differences between eslicarbazepine acetate and the other anticonvulsants. 
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Figure 22: Protective effect of oral administration of vehicle (V), eslicarbazepine acetate (ESL) 
300 mg/kg, carbamazepine (CBZ) 100 mg/kg, oxcarbazepine (OXC) 100 mg/kg and 
morphine (M) 64 mg/kg on the nociceptive reaction to intraperitoneal injection of acetic acid in 
mice. Each bar represents the mean ± S.E.M. for 10 animals. Statistical analysis of the data was 
evaluated by means of one-way ANOVA followed by Bonferroni’s multiple comparison test 
between all treated groups. Significances indicated by * (p < 0.05) and *** (p < 0.001) for all 
treated groups compared to eslicarbazepine acetate. Significances indicated by # p < 0.001 for 
all treated groups compared to vehicle. 
 
To assess the antinociception activity of eslicarbazepine acetate in the writhing test, the 
ED50 value was calculated. The ED50 value obtained for eslicarbazepine acetate 60 minutes after 
oral administration was 108.1 mg/kg (Figure 23). 
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Figure 23: ED50 value for eslicarbazepine acetate acetic acid-pain evoked response in the 
writhing test. Eslicarbazepine acetate was orally administered 60 minutes before the test. Data 
was fitted using nonlinear regression with a goodness of fit (R2) of 0.934. The Gompertz 
equation was used to derive the ED50 value (108.1 ± 5.4 mg/kg). 
 
Spanovic-Petrovic et al. (2008) published ED50 values for carbamazepine and 
oxcarbazepine nociception in the writhing test as being 38.9 mg/kg and 15.8 mg/kg, respectively. 
These values will be considered in the next section for evaluation of the antinociceptive activity 
of the referred drugs in the writhing test. 
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4 Determination of the Protective Index of Eslicarbazepine Acetate, Carbamazepine and 
Oxcarbazepine 
The potential analgesic activity of eslicarbazepine acetate in mice was evaluated in this 
experimental work using two different animal models of nociception: (i) the formalin paw test 
associated with the rotarod test and the open-field test (FRO); (ii) and the writhing test associated 
with the rotarod test and the open-field test (WRO). In order to ensure that the antinociceptive 
activity observed for a certain tested drug was due to its analgesic effect and not caused by drug 
induced neurotoxicity or drug induced motor impairment, sedation or stimulation, prior to the 
formalin paw test or to the writhing test, the rotarod and open-field tests were performed.  
Carbamazepine and oxcarbazepine are anticonvulsants that have been reported recently as 
having antinociceptive activity, so they were used here as comparison substances in the models 
developed in this experimental work (Kiguchi et al., 2004). Opiate drugs such as morphine have 
been widely used in the management of pain. Morphine was used here as a reference drug for 
development and implementation of the formalin paw and writhing tests (Miranda et al., 1992).  
It is clear that the animals treated with eslicarbazepine acetate up to 300 mg/kg, 
carbamazepine 100 mg/kg or oxcarbazepine 100 mg/kg presented no signs of neurotoxicity or 
motor impairment (observing the rotarod test results). Observing the open-field test result values, 
one can say that the animal’s ability to elevate its paw following formalin injection or the 
animal’s pain perception induced by the intraperitoneal injection of acetic acid were not 
compromised by the administered drugs at the former referred doses. An interesting observation 
was that oxcarbazepine 300 mg/kg, when administered orally 60 minutes before the test, 
displayed gross deficits in motor coordination (rotarod performance) but did not have pronounced 
effects on the open-field parameters. 
The ED50 values for antinociception in the formalin paw test and in the writhing test were 
determined using the doses 1 to 300 mg/kg of eslicarbazepine acetate, and the TD50 value for 
motor impairment in mice in the rotarod test was determined using the doses 1 to 450 mg/kg. The 
observed absence of effect upon exploratory behaviour or motor system on animals administered 
with the doses 1 to 300 mg/kg of eslicarbazepine acetate 60 minutes before the formalin paw and 
writhing tests, allowed the statement that the observed effect upon pain-evoked behaviour was 
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undoubtly antinociceptive. For carbamazepine the doses administered for ED50 value 
determination were 30 to 300 mg/kg.  
The dose that produced antinociceptive effect in 50 % of the mice tested in the formalin 
paw test was 41.4 mg/kg for eslicarbazepine acetate and 40.3 mg/kg for carbamazepine. The 
calculated protective index for eslicarbazepine acetate was 8.3 and for carbamazepine was 2.3. 
The oxcarbazepine ED50 and TD50 were obtained from the literature (Tomic et al., 2010; 
Stepanovic-Petrovic et al., 2008) and the protective index presented was calculated from the 
former referred values. The protective index, calculated as TD50 / ED50, is a measure of 
therapeutic tolerability (Learmonth et al., 2001). The values for antinociception in the formalin 
paw test, motor impairment and protective index in mice are shown in Table 3. 
 
Table 3: ED50, TD50 values and the corresponding Protective index (PI), with 95% confidence limits 
(95% CL) and correlation coefficient (R2) in inducing antinociception in the formalin paw test and motor 
impairment in mice. 
ED50 mg/kg TD50 mg/kg 
Substance (95%  CL) R2 (95%  CL) R2 PI 
2.6Oxcarbazepine 92.7 (-) ** - 239.4 (172.5-332.2) * -
40.3 (40.1-40.5) 1.000 91.0 (22.2-373.3) * - 2.3
Antinociception Motor Impairment
Eslicarbazepine Acetate 41.4 (38.9-44.0) 0.988 342.5 (329.8-355.3) 0.980 8.3
Carbamazepine
 
* value obtained from (Stepanovic-Petrovic et al., 2008); 
** value obtained from (Tomic et al., 2010). 
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The ED50 value for eslicarbazepine acetate antinociception in the writhing test was 
108.1 mg/kg, which corresponds to a therapeutic tolerability of 3.2. The carbamazepine and 
oxcarbazepine ED50 and TD50 and protective index values were obtained from the literature 
(Tomic et al., 2010; Stepanovic-Petrovic et al., 2008). The ED50 and TD50 values for 
antinociception in the writhing test and motor impairment in mice in the rotarod test are shown in 
Table 4. 
 
Table 4: ED50, TD50 values and the corresponding Protective index (PI), with 95% confidence limits 
(95% CL) and correlation coefficient (R2) in inducing antinociception in the writhing test and motor 
impairment in mice. 
ED50 mg/kg TD50 mg/kg 
Substance (95%  CL) R
2
(95%  CL) R
2
PI 
- 2.3
Oxcarbazepine 15.8 (11.1-22.3)* - 239.4 (172.5-332.2) * - 15.2
Carbamazepine 38.9 (31.2-48.2)* - 91.0 (22.2-373.3) *
3.2
Antinociception Motor Impairment
Eslicarbazepine Acetate 108.1 (97.4-118.9) 0.934 342.5 (329.8-355.3) 0.980
 
* value obtained from (Stepanovic-Petrovic et al., 2008) 
 
 The present results show that eslicarbazepine acetate has greater therapeutic tolerability in 
the formalin paw test than in the writhing test, suggesting that eslicarbazepine acetate is a better 
tolerated antinociceptive drug in the formalin paw test than in the writhing test. Carbamazepine 
and oxcarbazepine-induced antinociception in the formalin paw and in the writhing tests are in 
accordance with previously published information (Tomic et al., 2010; Aoki et al., 2006; 
Stepanovic-Petrovic et al., 2008). By comparison, eslicarbazepine acetate is about 3-fold more 
protective against formalin induced-pain than carbamazepine and oxcarbazepine. In the writhing 
test, eslicarbazepine acetate has a therapeutic tolerability between carbamazepine and 
oxcarbazepine. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
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In the present work, two in vivo models for evaluation of drugs with potential analgesic 
activity were developed and fully implemented. One model is constituted by the formalin paw 
test associated with the rotarod test and the open-field test (FRO). The other model is constituted 
by the writhing test, also associated with the rotarod test and the open-field test (WRO). Both 
models are performed in mice. In both models, the potential analgesic activity of the tested drugs 
was assessed by quantification of the protection that the referred drugs conferred against the 
insult pain-evoked behaviour, as compared to vehicle administered animals. The formalin paw 
test and the writhing test provide a measure of drug protection against pain. The rotarod test and 
the open-field tests provide means to assess motor toxicity and sedative, stimulant or motor 
behaviour impairment effects on drug treated mice, respectively. The protocol for the first 
referred model - FRO - consists of three tests occurring in two different days: on day 1, using the 
same group of mice for each dosing drug, the rotarod test is performed for 60 seconds 
immediately followed by the open-field test for 15 minutes; on day 2, using a new group of mice 
for each dosing drug, the formalin paw test is performed for 15 minutes, with the formalin being 
injected 15 minutes before the beginning of the test. The protocol for the second referred 
model - WRO - also consists of three tests occurring in two different days: on day 1 the rotarod 
test and the open-field test are performed as described for the FRO model; on day 2, using a new 
group of mice for each dosing drug, the writhing test is performed during 10 minutes, with the 
acetic acid being injected 5 minutes before the beginning of the test.  
Many authors have been neglecting the importance of the assessment of drug induced 
neurotoxicity or drug induced motor impairment, sedation or stimulation, prior to the nociception 
tests. For instance, if a drug administered to an animal induces motor impairment it will 
compromise the animal’s ability to elevate its paw following formalin injection or if a drug 
induces neurotoxicity, this can eventually disrupt or even kill neurons, and compromise the 
transmission and processing of pain signals in the brain or other parts of the nervous system, 
causing the absence of pain-evoked behaviour with this having no correlation with the 
antinociceptive effect of the administered drug. Observing the rotarod test results, it is clear that 
the animals treated 60 minutes before the test with eslicarbazepine acetate up to 300 mg/kg, 
carbamazepine 100 mg/kg or oxcarbazepine 100 mg/kg, presented no signs of neurotoxicity. The 
administered drugs at the former referred doses did not have any significant effect on the 
open-field test parameters (ambulation and rearing). Ambulation and rearing are parameters that 
allow the determination of the locomotor activity and exploratory activity, respectively. The 
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open-field test results show that eslicarbazepine acetate up to 300 mg/kg, carbamazepine 
100 mg/kg and oxcarbazepine 100 mg/kg have no effect on locomotor and exploratory activity of 
mice. Oxcarbazepine 300 mg/kg, when administered orally 60 minutes before the test, displayed 
gross deficits in motor coordination (rotarod performance) but did not have pronounced effects in 
the open-field parameters. So, oxcarbazepine 300 mg/kg results for the rotarod and the open-field 
tests emphasize the importance of assessing both drug induced neurotoxicity and drug induced 
motor impairment, sedation or stimulation, prior to the nociception tests. 
Opiate drugs such as morphine have been widely used in the management of pain. 
Morphine was used here as a reference drug for development and implementation of the formalin 
paw and writhing tests (Miranda et al., 1992). Morphine completely abolished the 
formalin-induced licking or biting as well as the number of writhes induced by acetic acid in 
mice, conferring a complete protection against pain. These results support the statement that the 
formalin paw and the writhing tests developed during this experimental work were implemented 
with success. 
Carbamazepine and oxcarbazepine are anticonvulsants that have been reported recently as 
having antinociceptive activity, so they were used here as comparison substances in the 
development and implementation of the models in this experimental work (Kiguchi et al., 2004). 
In the present studies, the putative sodium channel blockers carbamazepine (100 mg/kg) and 
oxcarbazepine (100 mg/kg) all produced statistically significant analgesic effects in the formalin 
paw test and writhing test which is consistent with previously published data (Shannon et al., 
2005; Stepanovic-Petrovic et al., 2008). The doses of the sodium channel blockers that produced 
analgesia in the formalin paw and writhing tests were smaller in magnitude than the doses 
required to produce effects in both the rotarod and open-field tests.  
The results obtained in the present study demonstrated that eslicarbazepine acetate 
exhibited antinociceptive activity in the two models tested (FRO and WRO). This effect was 
significant against chemically (acetic acid and formalin) induced nociception. The formalin paw 
test, characterized by two phases, is used to evaluate the mechanism by which an animal responds 
to moderate, continuous pain generated by the injured tissue (Abbott et al., 1995). The early 
phase (immediately after formalin injection) seems to be caused by C-fiber activation induced by 
the peripheral stimulus (Abbott et al., 1995). The late phase (starting approximately 15 min after 
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injection) appears to depend on the combination of an inflammatory reaction, activation of N-
methyl-D-aspartate (NMDA) and non-NMDA receptors, and the nitric oxide cascade (Davidson 
and Carlton, 1998) in the peripheral tissue and functional changes in the dorsal horn of the spinal 
cord (Abbott et al., 1995). The formalin is the most common substance to be used as noxious 
stimulus for intradermal injections (Wheeler-Aceto and Cowan, 1991). A range of 0.02  to 5 % of 
formalin solution concentration have been reported to be injected in mice, with the most 
frequently injected volume ranging from 20 to 25 µl (Tjolsen et al., 1992). In the formalin paw 
test developed and implemented in this experimental work 25 µl of formalin solution were 
injected subcutaneously in the hindpaw of the mouse at a concentration of 5 %, with the intent of 
inducing the late phase. The reason why only the late phase of the formalin paw test was assessed 
here is because it is described as being related to a peripheral inflammatory pain as is the writhing 
test (Collier et al., 1968; Hunskaar and Hole, 1987). In the writhing test, acetic acid activates 
directly peripheral nociceptors on the sensory nerve fibers by inducing capillary permeability and 
releasing endogenous substances that excite pain nerve endings (pro-inflammatory substances) 
producing inflammation of visceral (subdiaphragmatic) and subcutaneous (muscle wall) tissues 
(Cervero, 1995). This produces the characteristic ‘writhing response’: lengthwise stretches of the 
torso with a concomitant concave arching of the back and extensions of both hind limbs (Collier 
et al., 1968; Bentley et al., 1981). The acetic acid concentration most frequently used in the 
writhing test ranges from 0.6 to 0.8 % (v/v). Here a 0.8 % (v/v) acetic acid solution was chosen to 
be used for comparison purposes with the data published by Stepanovic-Petrovic (2008). In both 
the formalin paw and writhing tests, oral administration of eslicarbazepine acetate at doses 10 to 
300 mg/kg caused a statistically significant dose-dependent reduction of the pain evoked-
behaviour caused by the insult injection (formalin and acetic acid, respectively) as compared with 
the vehicle treated mice. Morphine completely abolished the pain evoked-behaviour in both the 
formalin paw and in the writhing tests, allowing the statement that the formalin paw test and 
writhing test were successfully developed and implemented. In the formalin paw test, when 
comparing the inhibition of pain induced by eslicarbazepine acetate as compared to 
carbamazepine, oxcarbazepine and morphine, eslicarbazepine acetate showed a more prominent 
protection against pain than the other tested anticonvulsants, although this effect was not 
statistically significant. The pain protection conferred by eslicarbazepine acetate was at the 
morphine protection level, abolishing completely the formalin pain-evoked behaviour. In the 
writhing test, eslicarbazepine acetate conferred an inhibition of the writhes at the same level as 
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morphine with no statistical significant difference between the two results. When comparing the 
protective effect of eslicarbazepine acetate with the protection conferred by carbamazepine and 
oxcarbazepine, eslicarbazepine acetate was more analgesic, with statistically significant 
differences between itself and the other two tested anticonvulsants. Eslicarbazepine acetate 
showed remarkable activity in the late phase of the formalin paw test and showed significant 
effect in the writhing test induced by acetic acid.  
The proof of concept for these in vivo models for evaluation of drugs with potential 
analgesic activity is dependent upon the establishment of a parallelism between the analgesic 
effect of the tested drug eslicarbazepine acetate, and the presence of the parent drug or its 
metabolites in mouse. Eslicarbazepine acetate is a sodium channel blocker, currently being used 
as an adjunct in the treatment of epilepsy, and shares with carbamazepine and oxcarbazepine the 
dibenzodiazepine nucleous bearing the 5-carboxamide substituent, but is structurally different at 
the 10, 11-positions (Benes et al., 1999; Hainzl et al., 2001). It is thought that these differences 
are on the basis of their different metabolic profiles. In humans carbamazepine undergoes 
oxidative metabolism leading to the formation of toxic epoxide carbamazepine metabolites and 
oxcarbazepine is bio transformed to S- and R- licarbazepine in a proportion of 4:1 (Almeida and 
Soares-da-Silva, 2003; Alves et al., 2008). Eslicarbazepine acetate in humans is quickly and 
extensively metabolized to S-licarbazepine to an extent of 95 - 98 % and to R-licarbazepine and 
oxcarbazepine to a very small extent (Almeida and Soares-da-Silva, 2003; Almeida and Soares-
da-Silva, 2004; Almeida et al., 2005). Eslicarbazepine acetate was specially designed to 
circumvent its further transformation to toxic epoxides and unnecessary production of 
enantiomers of its metabolites (Benes et al., 1999; Hainzl et al., 2001). Metabolic studies in mice 
showed that as in humans, eslicarbazepine acetate is rapidly hydrolysed to S-licarbazepine, being 
the mouse amongst small laboratory animals, the best whole animal model to better understand 
the eslicarbazepine acetate disposition in humans (Hainzl et al., 2001; Almeida and Soares-da-
Silva, 2007). Alves et al. (2008) studied the plasma and brain disposition of eslicarbazepine 
acetate and its metabolites in mouse following a single oral administration of eslicarbazepine 
acetate of 350 mg/kg, determining the concentrations of eslicarbazepine and its metabolites. 
These authors observed that eslicarbazepine acetate in mice is rapidly and extensively 
metabolized, lacking the detection of the parent drug (eslicarbazepine acetate) at the first 
sampling point (withdrawn 0.25 hours after administration) and finding at this time-point large 
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amounts of S-licarbazepine in plasma and brain. Alves et al. (2008) determined that 
S-licarbazepine represents 85 % of the total brain drug exposure and oxcarbazepine represents 
15 %, with a tmax (the time that it takes to reach the maximum concentration of drug) of 1 hour for 
both drugs. The present study demonstrates that eslicarbazepine acetate orally administered 
1 hour before the formalin paw test as well as 1 hour before the writhing test showed great 
efficacy on protecting mice from pain. As described before, eslicarbazepine acetate transforms 
rapidly into its major metabolite S-licarbazepine and at 1 hour post oral administration one can 
find the maximum concentration of S-licarbazepine in the brain.  
The primary mechanism of action of S-licarbazepine is blockade of voltage-dependent 
sodium channels (Benes et al., 1999; Almeida and Soares-da-Silva, 2007). The affinity of 
S-licarbazepine for the inactivated state of the sodium channel is similar to that of 
carbamazepine, but its affinity for the resting state of the sodium channel is 3-fold lower 
(Bonifacio et al., 2001). S-licarbazepine inhibits the sodium-dependent release of 
neurotransmitters, with a potency comparable to that of carbamazepine and oxcarbazepine 
(Parada and Soares-da-Silva, 2002). Voltage-activated sodium channels induces the initial rapid 
membrane depolarization during an action potential in neural cells and are responsible for the 
propagation of the action potential, allowing the transmission of pain. The pain function of 
sodium channels can be up-regulated in the inflammatory conditions (Sahebgharani et al., 2006), 
the conditions present in both the late phase of the formalin paw test and in the writhing test. 
Because carbamazepine and oxcarbazepine are sodium channel blockers as is eslicarbazepine 
acetate active metabolite S-licarbazepine, because these anticonvulsants showed analgesic 
activity in the pain models developed in this experimental work, although with different 
protective indices, and because sodium channel blockers are involved in the process of 
transmission of pain, the most likely explanation for the  analgesic activity of eslicarbazepine 
acetate is that part of the antinociceptive response of S-licarbazepine is at the voltage-gated 
sodium channels level. The results obtained for protective index of eslicarbazepine acetate, when 
compared with the protective indices for carbamazepine and oxcarbazepine show that 
eslicarbazepine acetate is just about 3-fold more protective against formalin induced-pain than 
carbamazepine and oxcarbazepine. In the writhing test, eslicarbazepine acetate showed a 
protective index between carbamazepine and oxcarbazepine. The protective index is considered a 
measure of therapeutic tolerability, as being the relative safety of the drug for a particular 
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treatment (Learmonth et al., 2001).  
In conclusion, one can state that the two models developed here FRO and WRO are able to 
evaluate the analgesic activity of drugs in mice, with sensitivity to different doses of an analgesic 
drug. The rotarod and the open-field tests together play an important role in the developed models 
and many authors have been neglecting the importance of drug induced neurotoxicity or drug 
induced motor impairment, sedation or stimulation, as conditions that can mask the true analgesic 
effect of a drug. The data supports the statement that both models FRO and WRO are tools of 
great importance for the evaluation of the analgesic activity of both old and new drugs.  
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